| Bioactivity | MMG-11 is a potent and selective human TLR2 antagonist with low cytotoxicity. MMG-11 inhibits both TLR2/1 and TLR2/6 signaling with IC50s of 1.7 µM for Pam3CSK4-induced hTLR2/1 and 5.7 µM for Pam2CSK4-induced hTLR2/6 responses[1]. | ||||||||||||
| Invitro | MMG-11 neither shows cellular toxicity nor interference with signaling induced by other TLR agonists, IL-1β or TNF. MMG-11 (0.01-100 µM) shows no cytotoxic effects up to 100 µM in peripheral blood mononuclear cells (PBMCs)[1]. Cell Cytotoxicity Assay[1] Cell Line: | ||||||||||||
| Name | MMG-11 | ||||||||||||
| CAS | 313254-94-3 | ||||||||||||
| Formula | C15H14O7 | ||||||||||||
| Molar Mass | 306.27 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Grabowski M, et al. Identification of a pyrogallol derivative as a potent and selective human TLR2 antagonist by structure-based virtual screening. Biochem Pharmacol. 2018 Aug;154:148-160. |